School of Dentistry Clinic Data Links Bisphosphonates to Jaw Osteonecrosis
Study is among the first to acknowledge correlation between the common medications and jawbone death.
By Beth Dunham
01/09/09

Even short-term use of common oral osteoporosis drugs may leave the jaw vulnerable to devastating necrosis, according to a new USC School of Dentistry study appearing in the January 1 Journal of the American Dental Association (JADA).
“Oral Bisphosphonate Use and the Prevalence of Osteonecrosis of the Jaw: An Institutional Inquiry” is the first large institutional study in the
U.S. to investigate the relationship between oral bisphosphonate use
and jaw bone death, said principal investigator Parish Sedghizadeh,
assistant professor of clinical dentistry with the USC School of
Dentistry.
After
controlling for referral bias and other patient health factors, nine of
208 School of Dentistry patients who take or have taken Fosamax for any
length of time were diagnosed with osteonecrosis of the jaw (ONJ). The
study’s results are in contrast to drug makers’ prior assertions that
bisphosphonate-related ONJ risk is only noticeable with intravenous use
of the drugs, not oral usage, Sedghizadeh said.
“We’ve been told that the risk with oral bisphosphonates is negligible, but four percent is not negligible,” he said.
Most
doctors who have prescribed bisphosphonates have not told patients
about any oral health risks associated with the use of the drugs,
despite even short-term usage posing a risk due to the drug’s tenacious
10-year half-life in bone tissue. Lydia Macwilliams of Los Angeles said
no one told her about the risk posed by her three years of Fosamax
usage until she became a patient of Sedghizadeh at the School of
Dentistry.
“I was surprised,” she said. “My doctor who prescribed the Fosamax didn’t tell me about any possible problems with my teeth.”
Macwilliams
was especially at risk for complications because she was to have three
teeth extracted. The infection is a biofilm bacterial process, meaning
that the bacteria infecting the mouth and jaw tissues reside within a
slimy matrix that protects the bacteria from many conventional
antibiotic treatments, and bisphosphonate use may make the infection
more aggressive in adhering to the jaw, Sedghizadeh said. The danger is
especially pronounced with procedures that directly expose the jaw
bone, such as tooth extractions and other oral surgery.
After
her extractions, two of the three extraction sites had difficulty
healing due to infection, Macwilliams said. Luckily, with treatment as
well as the rigorous oral hygiene regimen that USC dentists developed
especially for patients with a history of bisphosphonate usage, the
remaining sites slowly but fully healed.
“It took about a year to heal,” she said, “but it’s doing just fine now.”
Sedghizadeh
hopes to have other researchers confirm his findings and thus encourage
more doctors and dentists to talk with patients about the oral health
risks associated with the widely used drugs. The results confirm the
suspicions of many in the oral health field, he said.
“Here
at the School of Dentistry, we’re getting two or three new patients a
week that have bisphosphonate-related ONJ,” he said, “and I know we’re
not the only ones seeing it.”